Highest-materiality recent filing
Monte Rosa Q2 2026 net loss $43.4M; cash $626M; MRT-8102 GFORCE-1 readout H2 2026
Net loss of $43.4M in Q2 2026 vs $12.3M in Q2 2025; collaboration revenue $9.0M vs $23.2M.
Monte Rosa stockholders elect three Class II directors, ratify Deloitte as auditor
Andrew Schiff, M.D., Chandra P. Leo, M.D., and Anthony Manning, Ph.D. elected as Class II directors for three-year terms ending 2029.
Monte Rosa Q1 net loss $44.5M; cash $671M; multiple pipeline advances
Net loss of $44.5M vs net income of $46.9M in Q1 2025; collaboration revenue fell to $4.2M from $84.9M.
Q4 net loss $46.1M vs $13.4M in Q4 2024; full-year net loss decreased to $38.6M from $72.7M.
Monte Rosa Therapeutics PAO Edmund Dunn to retire; Matthew Bowen appointed successor
Edmund Dunn, SVP, Corporate Controller and PAO, to retire effective April 3, 2026; no severance or disagreement.
Monte Rosa prices $300M public offering of common stock and pre-funded warrants
Offering of 11,125,000 shares at $24.00/share and pre-funded warrants for 1,375,000 shares at $23.9999 each.
Monte Rosa reports positive interim Phase 1 data for MRT-8102; hsCRP reduced 85% in 4 weeks
In subjects with elevated CVD risk, MRT-8102 reduced hsCRP by 85% after 4 weeks; 94% achieved hsCRP <2 mg/L (median baseline 6.3 mg/L).
Effective January 7, 2026, company terminated the ATM prospectus under its shelf registration.
MRT-2359 + enzalutamide shows 100% PSA response in AR-mutant mCRPC; Phase 2 planned 2026
In 14 evaluable mCRPC patients, overall DCR 64% (9/14); in AR-mutant subset (n=4), 100% PSA response rate and 100% DCR, with 2 RECIST partial responses.
Monte Rosa reports Q3 net loss $27.1M; second Novartis deal with $120M upfront
Net loss $27.1M vs $23.9M YoY; collaboration revenue $12.8M (vs $9.2M).
Monte Rosa and Novartis expand collaboration for immune-disease degraders; upfront $120M
Monte Rosa receives $120M upfront from Novartis under new collaboration for degraders in immune-mediated diseases.
Monte Rosa Q2 net loss narrows to $12.3M on $23.2M collaboration revenue; cash runway to 2028
Collaboration revenue $23.2M (vs $4.7M YoY) from Novartis license; net loss improved to $12.3M from $30.3M.
Monte Rosa Therapeutics elects three Class I directors, ratifies auditor at 2025 annual meeting
Elected Christine Siu, Kimberly Blackwell, and Jan Skvarka as Class I directors for three-year terms ending in 2028.
Monte Rosa Q1 net income $46.9M on Novartis revenue; pipeline advances
Net income of $46.9M vs net loss of $32.0M a year ago; collaboration revenue $84.9M from Novartis.
Monte Rosa Q4 net income $13.4M; Ph1 MRT-6160 >90% VAV1 deg, MRT-2359 CRPC response
Q4 2024 net income $13.4M vs net loss $33.3M in Q4 2023; collaboration revenue $60.6M from Novartis/Roche deals.
Monte Rosa announces 2025 milestones and $377M cash position funding into 2028
Preliminary cash, equivalents, and securities of $377.0M as of Dec 31, 2024; funds operations into 2028.
Monte Rosa Therapeutics appoints Eric A. Hughes, M.D., Ph.D. to Board of Directors
Dr. Hughes is Executive VP, Global R&D and Chief Medical Officer at Teva Pharmaceuticals; previously at Vertex, Novartis, BMS.
Monte Rosa sets RP2D for MRT-2359 at 0.5 mg/day 21/7 schedule; safety, PD data positive
RP2D selected: 0.5 mg daily on 21-days-on/7-days-off schedule based on favorable safety and ~60% GSPT1 degradation.
Monte Rosa reports Q3 net loss $23.9M; announces Novartis deal for VAV1 degraders with $150M upfront
Net loss of $23.9M for Q3 2024; collaboration revenue of $9.2M from Roche.
Monte Rosa licenses VAV1 degrader MRT-6160 to Novartis for $150M upfront
Novartis gets exclusive worldwide rights to develop, manufacture, and commercialize VAV1 MGDs including MRT-6160.
Monte Rosa Q2 net loss $30.3M; cash $267.1M; IND cleared for MRT-6160
Net loss $30.3M for Q2 2024 vs $32.0M in Q1; collaboration revenue $4.7M from Roche deal.
Monte Rosa: MRT-2359 dose update; MRT-6160 IND for autoimmune diseases
MRT-2359 Phase 1/2: favorable safety at 0.5 mg 21/7 schedule; evaluating 0.75 mg cohort; RP2D and updated data expected H2 2024.
Monte Rosa Therapeutics 2024 annual meeting results: directors elected, auditor ratified
Markus Warmuth, M.D. elected with 39,473,886 votes for, 84,415 withheld; Ali Behbahani, M.D. with 23,794,947 for, 15,763,354 withheld.
Monte Rosa Therapeutics promotes three executives to CSO, CBO/CLO, and COO
Sharon Townson, Ph.D., promoted to Chief Scientific Officer; previously CTO.
Monte Rosa prices $100M public offering of common stock and pre-funded warrants
Priced 10.6M shares at $4.70/share and pre-funded warrants for 10.6M shares at $4.6999/warrant; gross proceeds $100M.
Monte Rosa Q1 net loss $32M; pipeline advances with MRT-2359, MRT-6160, MRT-8102 milestones
Q1 2024 net loss $32.0M; cash $197.8M (down from $237.0M Dec 2023), sufficient into H1 2026.
Monte Rosa CSO Owen Wallace departs May 17 to become CEO at UK biotech; remains adviser
Owen Wallace resigns as CSO effective May 17, 2024, to become CEO of a UK-based biotech company.
Monte Rosa reports Q4 2023 net loss $33.3M; cash into H1 2026; key pipeline milestones on track
Net loss Q4 2023 $33.3M ($30.8M prior year); FY net loss $135.4M; cash $237M, runway into H1 2026.
Monte Rosa outlines 2024 milestones: Fast Track for MRT-2359, MRT-6160 Phase 1, cash into H1 2026
FDA Fast Track Designation for MRT-2359 in previously treated metastatic SCLC with L-MYC or N-MYC expression.
Monte Rosa Q3 net loss $34.9M; cash runway into H1 2026 after Roche deal and $25M offering
Net loss $34.9M vs $27.3M in Q3 2022; R&D expenses $28.3M, G&A $8.7M.
Monte Rosa raises $25M via pre-funded warrant offering at $2.4999 per share
Gross proceeds ~$25M from sale of pre-funded warrants to purchase 10,000,400 shares.
Monte Rosa signs $50M upfront Roche collaboration for MGDs; MRT-2359 shows early efficacy
Upfront payment of $50M from Roche; potential milestones >$2B for initial oncology/neurology targets.
Monte Rosa Q2 net loss $35.2M, CFO resigns; cash sustains into 2025
Net loss of $35.2M for Q2 2023 vs $26.5M in Q2 2022; R&D expenses $29.1M.
Monte Rosa appoints former Momenta CSO Anthony Manning to Board
Board expanded from 8 to 9 directors; Dr. Manning fills newly created vacancy, effective July 25, 2023.
Monte Rosa Therapeutics stockholders approve officer liability amendment, elect directors
Amendment to certificate of incorporation to limit officer liability as per Delaware law approved (42.5M for, 567k against).
Monte Rosa Q1 net loss $32M; cash $237M; MRT-2359 data on track for H2 2023
Net loss $32M in Q1 2023 vs $23.9M in Q1 2022; R&D expenses $26.8M vs $17.9M.
Monte Rosa Therapeutics appoints Jan Skvarka to Board of Directors
Appointed Jan Skvarka, Ph.D., MBA to the Board, effective March 23, 2023.
Monte Rosa reports FY 2022 net loss of $108.5M; MRT-2359 Phase 1/2 data expected H2 2023
FY 2022 net loss $108.5M (vs $74.0M in 2021); cash & securities $268.1M, runway into 2025.
Monte Rosa Therapeutics outlines 2023 milestones; MRT-2359 Fast Track designation from FDA
MRT-2359 granted FDA Fast Track for previously treated metastatic NSCLC with L-MYC or N-MYC expression.
Monte Rosa Q3 net loss $27.3M; MRT-2359 Phase 1/2 dosing initiated
Net loss of $27.3M in Q3 2022 vs $19.8M in Q3 2021; R&D expenses rose to $21.3M.
Monte Rosa holds KOL webinar on MRT-2359 hosted by Cowen on Oct 24, 2022
Presented at KOL webinar hosted by Cowen on MRT-2359, a targeted protein degrader.
Monte Rosa Q2 2022 net loss $26.5M; IND submitted for MRT-2359
Net loss of $26.5M for Q2 2022, compared to $18.4M in Q2 2021.
Monte Rosa stockholders elect two Class I directors, ratify Deloitte as auditor
Christine Siu elected with 40,031,134 votes for, 1,535,338 withheld, 2,219,497 broker non-votes.
Monte Rosa Q1 net loss $23.9M; IND for MRT-2359 expected mid-2022
Net loss $23.9M for Q1 2022 vs $12.3M in Q1 2021; R&D spend $17.9M.
Monte Rosa reports Q4 2021 net loss $23.4M; cash $351.4M; on track for MRT-2359 IND mid-2022
Net loss Q4 2021 $23.4M vs $19.7M in Q4 2020; FY 2021 loss $74.0M vs $35.9M in 2020.
Monte Rosa presents at J.P. Morgan Healthcare Conference; no specific details disclosed in filing
Company delivered revised corporate presentation at 40th Annual J.P. Morgan Healthcare Conference on Jan 10, 2022.
Monte Rosa Therapeutics enters 128-month lease for 63,327 sq ft in Boston at $95/sqft base rent
Leased 63,327 sq ft at 321 Harrison Ave, Boston for office/lab space; term starts April 1, 2022.
Monte Rosa names first development candidate MRT-2359 targeting GSPT1; Q3 net loss $19.8M
Selected MRT-2359 as first development candidate; initiated IND-enabling studies for mid-2022 IND submission.
Monte Rosa Q2 net loss $18.4M; $255.6M IPO extends cash into late 2024
R&D expenses $14.6M (Q2 2020: $4.9M), G&A $3.5M ($0.5M) as headcount and lab activities expanded.
On May 28, 2024, the Compensation, Nomination and Corporate Governance Committee of Board of Directors of Monte Rosa Therapeutics, Inc. (the “Company”) promoted Jennifer Champoux, the Company’s Chief People and Operations Officer, to serve as the Company’s Chief Operating Officer, effective as of May 28, 2024
On April 29, 2024, Owen Wallace, the Chief Scientific Officer of Monte Rosa Therapeutics, Inc. (the "Company"), resigned from the Company effective May 17, 2024 (the “Effective Date”).
the Board appointed Anthony M. Manning, Ph.D. to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from eight (8) to nine (9) directors.
the Board appointed Jan Skvarka, Ph.D., MBA to join the Board, effective as of March 23, 2023.
Max materiality 0.90 · Median 0.60 · Most common event earnings